Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Change in Cash (2016 - 2025)

Neuroone Medical Technologies (NMTC) has disclosed Change in Cash for 14 consecutive years, with -$3.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Cash fell 823.81% year-over-year to -$3.0 million, compared with a TTM value of $2.4 million through Dec 2025, up 256.94%, and an annual FY2025 reading of $5.1 million, up 232.31% over the prior year.
  • Change in Cash was -$3.0 million for Q4 2025 at Neuroone Medical Technologies, down from -$1.5 million in the prior quarter.
  • Across five years, Change in Cash topped out at $9.3 million in Q4 2021 and bottomed at -$3.5 million in Q4 2022.
  • Average Change in Cash over 5 years is -$178374.8, with a median of -$939973.5 recorded in 2023.
  • Peak annual rise in Change in Cash hit 924.8% in 2025, while the deepest fall reached 823.81% in 2025.
  • Year by year, Change in Cash stood at $9.3 million in 2021, then tumbled by 137.63% to -$3.5 million in 2022, then grew by 24.37% to -$2.6 million in 2023, then soared by 87.67% to -$325692.0 in 2024, then crashed by 823.81% to -$3.0 million in 2025.
  • Business Quant data shows Change in Cash for NMTC at -$3.0 million in Q4 2025, -$1.5 million in Q3 2025, and $6.7 million in Q2 2025.